AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy: Difference between revisions
< AHA
(Created page with "__NOTOC__ {{Stroke}} {{CMG}}; {{AE}} {{AO}} ==Overview== ==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == ==References== {{refl...") |
m (Bot: Adding CME Category::Cardiology) |
||
(2 intermediate revisions by one other user not shown) | |||
Line 2: | Line 2: | ||
{{Stroke}} | {{Stroke}} | ||
{{CMG}}; {{AE}} {{AO}} | {{CMG}}; {{AE}} {{AO}} | ||
==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)<ref name="pmid24503673">{{cite journal| author=Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL et al.| title=Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. | journal=Stroke | year= 2014 | volume= | issue= | pages= | pmid=24503673 | doi=10.1161/01.str.0000442009.06663.48 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24503673 }} </ref> == | |||
===Postmenopausal Hormonal Therapy=== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == | |colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit) | ||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' HT (CEE with or without [[medroxyprogesterone]]) should not be used for primary or secondary prevention of stroke in postmenopausal women. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' Selective estrogen receptor modulators, such as [[raloxifene]], [[tamoxifen]], or [[tibolone]], should not be used for primary prevention of [[stroke]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Aging-associated diseases]] | [[Category:Aging-associated diseases]] | ||
Line 23: | Line 31: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 19:35, 14 March 2016
Stroke Main page | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy On the Web | |
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)[1]
Postmenopausal Hormonal Therapy
Class III (No Benefit) |
"1. HT (CEE with or without medroxyprogesterone) should not be used for primary or secondary prevention of stroke in postmenopausal women. (Level of Evidence: A) " |
"2. Selective estrogen receptor modulators, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke. (Level of Evidence: A) " |
References
- ↑ Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL; et al. (2014). "Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. doi:10.1161/01.str.0000442009.06663.48. PMID 24503673.